Therapeutic drug monitoring of β-lactams in critically ill patients: Proof of concept

International Journal of Antimicrobial Agents

Volumn 36, Issue 4, 2010, Pages 332-339

  Roberts, Jason A ^a,b   Ulldemolins, Marta ^a,c   Roberts, Michael S ^a,d   McWhinney, Brett ^b   Ungerer, Jacobus ^b   Paterson, David L ^b,e   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Lactam antibiotic; Adverse events; Bolus dosing; Continuous infusion; Extended infusion; Pharmacodynamics; Pharmacokinetics; TDM

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; DICLOXACILLIN; ERTAPENEM; FLUCLOXACILLIN; MEROPENEM; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CHOLESTASIS; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDICATION; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG UTILIZATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; UNSPECIFIED SIDE EFFECT; UROSEPSIS; WOUND;

ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; BACTERIAL INFECTIONS; BETA-LACTAMS; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77954849218     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.06.008     Document Type: Article

References (34)

1. Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851.
2. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., Jimenez-Jimenez F.J., Perez-Paredes C., Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751.
3. Garnacho-Montero J., Aldabo-Pallas T., Garnacho-Montero C., Cayuela A., Jiménez R., Barroso S., et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006, 10:R111.
4. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535.
5. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
6. Bakker-Woudenberg I.A., Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med 1990, 16(Suppl. 3):S229-S234.
7. Gomez C.M., Cordingly J.J., Palazzo M.G. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999, 43:1798-1802.
8. Lipman J., Wallis S.C., Rickard C.M., Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001, 27:363-370.
9. Roberts J.A., Kirkpatrick C.M.J., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
10. Roberts J.A., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration?. Crit Care Med 2009, 37:926-933.
11. Joukhadar C., Frossard M., Mayer B.X., Brunner M., Klein N., Siostrzonek P., et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29:385-391.
12. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002, 19:349-353.
13. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
14. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004, 2:289-300.
15. Ariano R.E., Nyhlén A., Donnelly J.P., Sitar D.S., Harding G.K., Zelenitsky S.A. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39:32-38.
16. Li C., Du X., Kuti J.L., Nicolau D.P. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51:1725-1730.
17. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
18. McKinnon P.S., Paladino J.A., Schentag J.J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351.
19. Tam V.H., Schilling A.N., Neshat S., Poole K., Melnick D.A., Coyle E.A. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:4920-4927.
20. Craig W. Pharmacokinetic and experimental data on β-lactam antibiotics in the treatment of patients. Eur J Clin Microbiol Infect Dis 1984, 3:575-578.
21. Mouton J.W., Vinks A.A., Punt N.C. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997, 41:733-738.
22. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W.A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988, 158:831-847.
23. Vogelman B.S., Craig W.A. Postantibiotic effects. J Antimicrob Chemother 1985, 15(Suppl. A):37-46.
24. Mouton J.W., den Hollander J.G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994, 38:931-936.
25. Mouton J.W., Vinks A.A. Continuous infusion of β-lactams. Curr Opin Crit Care 2007, 13:598-606.
26. Roosendaal R., Bakker-Woudenberg I.A., van den Berghe-van Raffe M., Vink-van den Berg J.C., Michel B.M. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur J Clin Microbiol Infect Dis 1989, 8:878-887.
27. Vogelman B., Craig W.A. Kinetics of antimicrobial activity. J Pediatr 1986, 108:835-840.
28. Ryan D.M. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993, 31(Suppl. D):1-16.
29. Udy A.A., Roberts J.A., Boots R.J., Paterson D.L., Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010, 49:1-16.
30. McWhinney B.C., Wallis S.C., Hillister T., Roberts J.A., Lipman J., Ungerer J.P.J. Analysis of twelve beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatograph B 2010, 878:2039-2043.
31. Buijk S.L., Gyssens I.C., Mouton J.W., Van Vliet A., Verbrugh H.A., Bruining H.A. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49:121-128.
32. Lipman J., Gomersall C.D., Gin T., Joynt G.M., Young R.J. Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999, 43:309-311.
33. Lipman J., Wallis S.C., Rickard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43:2559-2561.
34. Joynt G.M., Lipman J., Gomersall C.D., Young R.J., Wong E.L., Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001, 47:421-429.